Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Lenalidomide is a synthetic compound derived by modifying the chemical structure of thalidomide. It belongs to the second generation of immunomodulatory drugs (IMiDs) and possesses pleiotropic properties. Even if lenalidomide has been shown to be active in the treatment of several hematologic malignancies, this review article is mostly focalized on its mode of action in multiple myeloma. The present paper is about the direct and indirect antitumor effects of lenalidomide on malignant plasmacells, bone marrow microenvironment, bone resorption and host’s immune response. The molecular mechanisms and targets of lenalidomide remain largely unknown, but recent evidence shows cereblon (CRBN) as a possible mediator of its therapeutical effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450 · cited 1×
“a significant benefit in overall survival (38 versus 31,6 months, P < 0, 045) for those patients initially randomized to be treated with lenalidomide-dexamethasone combination [8, 26].”
BackgroundLenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233 · cited 1×
“a significant benefit in overall survival (38 versus 31,6 months, P < 0, 045) for those patients initially randomized to be treated with lenalidomide-dexamethasone combination [8, 26].”
BackgroundRajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933 · cited 1×
“More recently, several studies have compared the activity of lenalidomide combined with high or reduced dose of dexamethasone in newly diagnosed MM patients [28, 29].”
BackgroundEfficacy of Lenalidomide in Myelodysplastic Syndromes
List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R., & Zeldis, J. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041668 · Cited by 880
Chu, Z.-L., McKinsey, T. A., Liu, L., Gentry, J. J., Malim, M. H., & Ballard, D. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.19.10057 · Cited by 872 · cited 1×
“Moreover, long term treatment of malignant PCs with lenalidomide determines a downregulation of NF-kB activity, which results in a reduction of antiapoptotic proteins including cIAP2 [65] and FLIP [66].”
BackgroundRichardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268862 · Cited by 861
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356063 · Cited by 607
Cited by
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Molecular Glues for Targeted Protein Degradation: From Serendipity to Rational Discovery
Dong, G., Ding, Y., He, S., & Sheng, C. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00895 · Cited by 369
Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs
D'Souza, C., Prince, H. M., & Neeson, P. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.632399 · Cited by 52
Metadata
- Authors
- Martiniani, R., Di Loreto, V., Di Sano, C., Lombardo, A., & Liberati, A. M.
- Venue
- Advances in Hematology
- Publisher
- Hindawi Limited
- Published
- 2012
- Volume
- 2012
- Pages
- 1-11
- ISSN
- 1687-9104 (ISSN-L)
- 1687-9112
- OpenAlex
- W2163060468
- Cited by
- 63
- References
- 13
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma. https://app.cochat.ai/papers/10.1155/2012/842945
- The paper
- Martiniani, R., Di Loreto, V., Di Sano, C., Lombardo, A., & Liberati, A. M. (2012). Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma. Advances in Hematology. https://doi.org/10.1155/2012/842945
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.